Last
Update:
September 09, 2008
Perinatal Journal Data are integrated with Perinatal Conference Data in
the Perinatal Data Page.
Pediatric Journal Data are integrated with Pediatric Conference Data in
the Pediatric Data Page
 Documents identified with this icon
are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader.
XVII
International AIDS Conference
|
-
Can efavirenz be used in HIV-infected patients with preceding severe
cutaneous reactions to nevirapine?
B. Purandare, V. Purandare, D. Padhya, et al
Abstract
-
Quantifying the risks and benefits of efavirenz (EFV) use in HIV-infected
women of childbearing age in the US
H. Hsu, C. Rydzak, K. Cotich, et al
Abstract
-
A low dose of efavirenz provides adequate efavirenz plasma concentrations
in Thai HIV-1 infected adults
A.
Avihingsanon, J. Van der Lug, M. Gorowara,
et al
Abstract
-
Efavirenz in pregnancy: maternal characteristics of women who become
pregnant on EFV-containing regimen
and neonatal effects
M.I.
Gonzalez-Tome, M. Fernandez-Ibieta J. Ramos Amador
et al
Abstract
-
Efficacy of subsequent efavirenz-based regimen in HIV-infected patients
with preceding discontinuation of nevirapine
W. Manosuthi, S. Chimsuntorn, S. Sungkanuparph -
Effect of intermittent versus continuous exposure to efavirenz on
depressive symptoms in HIV-infected adults
in West Africa (Trivacan ANRS 1269 trial)
F. Marcellin, R. Moh, M.P. Carrieri, et al
Abstract
-
Plasma efavirenz (EFV) level and CYP450 2B6 genotype in HIV patients on
HAART in Southern China
S.T. Liu, K.W. To, R.C.Y. Chan, et al
Abstract
POWERPOINT POSTER PRESENTATION
A prospective,
randomized, open label trial of efavirenz versus lopinavir/ritonavir based HAART
among antiretroviral
therapy naïve, HIV infected individuals presenting for care with CD4 cell counts
<200/mm3 in Mexico
J Sierra Madre
Poster Presentation
POWERPOINT POSTER PRESENTATION
Once-a-day pediatric
HAART with DDI+3TC+EFV in Burkina Faso - a phase II Trial (ANRS 12103 trial)
P Msellati
Poster Presentation
9th Int. Workshop on Clinical
Pharmacology of HIV Therapy
|
CONFERENCE PDF PRESENTATION
Factors influencing efavirenz and nevirapine plasma concentration: effect of
ethnicity, weight and comedication.
Stoehr W, Back D, Dunn D, et al
Presentation
-
A WEEK IN REVIEW
FEATURED REPORT
Outcomes of Abacavir- and Efavirenz-based HAART: Comparison of ACTG
5095 Trial Results with
Observational Cohort Studies
M Mugavero, M May, H Ribaudo, et al
Abstract
-
POSTER
Efavirenz Induces CYP450 2B6 Activity as Measured by Bupropion
Hydroxylation in Healthy Subjects
S Robertson, F
Maldarelli, V Natarajan, et al
 PDF
Poster
Abstract
-
POSTER
Influence of NRTI Choice and Efavirenz vs Lopinavir Treatment Options on
Lipoatrophy-associated
Adipose Tissue Toxicity: A Longitudinal Study
E Hammond, B McKinnon, C Pace, et al
PDF
Poster
Abstract
-
Presence of Minor Populations of Y181C Mutants Detected by Allele-specific
PCRand Risk of
Efavirenz Failure in Treatment-naïve Patients: Results of an ACTG 5095
Case-cohort Study
R Paredes, C Lalama, H Ribaudo, et al
Abstract
-
Genetic
Variation in Accessory Metabolic Pathways Is Associated with Extreme Efavirenz
Exposure
in
Individuals with Impaired CYP2B6 Function
J di Lulio, M Rotger, R Lubomirov, et al
Abstract
-
NNRTI,
Efavirenz and Nevirapine, Induce Leukocyte-Endothelial Cell Interactions in
the Microvasculature
M Andrade, F Baixauli, A Blas-Garcia, et al
Abstract
-
Intracellular Accumulation of Tenofovir and Emtricitabine in vitro
Highlight the Inhibitor Role of
Efavirenz for Multridrug Resistance-Associated Protein 1, MRP1
L Bousquet, A Pruvost, N Didier, et al
Abstract
-
Acute
Inhibition of Mitochondrial Function by Efavirenz Induces Changes in Cellular
Lipid Metabolism
A Blas-Garcia, M Rocha, F
Baixauli, et al
Abstract
-
POSTER
Fasted Lipid Changes
after Administration of Maraviroc or Efavirenz in Combination with
Zidovudine
and Lamivudine for 48 weeks to Treatment-naïve HIV-infected
Patients
E DeJesus, S Walmsley,
C Cohen, et al
PDF
Poster
Abstract
-
Effect
of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A
Prospective, Randomized,
Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial
Treatment of HIV-1 Infection
S Riddler, R Haubrich, G DiRienzo, et al
Abstract
|
|
|
|
Conference
Archives